Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥399.43 Million ≈ $58.45 Million USD) by net assets (CN¥12.43 Billion ≈ $1.82 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen Hepalink Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
0.015x |
|
ACME Solar Holdings Limited
NSE:ACMESOLAR
|
0.151x |
|
Ourpalm
SHE:300315
|
0.013x |
|
STROEER (UNSP.ARD)/4/1
F:SAXB
|
N/A |
|
Austevoll Seafood ASA
OL:AUSS
|
0.304x |
|
Xinhuanet Co Ltd
SHG:603888
|
0.034x |
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
0.046x |
|
East Group Co Ltd
SHE:300376
|
0.098x |
Annual Cash Flow Conversion Efficiency for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Shenzhen Hepalink Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥12.08 Billion ≈ $1.77 Billion |
CN¥1.71 Billion ≈ $250.66 Million |
0.142x | -21.14% |
| 2024-12-31 | CN¥12.20 Billion ≈ $1.79 Billion |
CN¥2.19 Billion ≈ $321.07 Million |
0.180x | +441.34% |
| 2023-12-31 | CN¥11.99 Billion ≈ $1.75 Billion |
CN¥398.22 Million ≈ $58.27 Million |
0.033x | +154.47% |
| 2022-12-31 | CN¥12.41 Billion ≈ $1.82 Billion |
CN¥-756.61 Million ≈ $-110.72 Million |
-0.061x | -10499.68% |
| 2021-12-31 | CN¥11.52 Billion ≈ $1.69 Billion |
CN¥-6.63 Million ≈ $-970.08K |
-0.001x | -118.04% |
| 2020-12-31 | CN¥11.69 Billion ≈ $1.71 Billion |
CN¥37.28 Million ≈ $5.46 Million |
0.003x | +110.47% |
| 2019-12-31 | CN¥7.47 Billion ≈ $1.09 Billion |
CN¥-227.60 Million ≈ $-33.31 Million |
-0.030x | -128.48% |
| 2018-12-31 | CN¥6.24 Billion ≈ $913.80 Million |
CN¥667.87 Million ≈ $97.73 Million |
0.107x | +301.93% |
| 2017-12-31 | CN¥7.69 Billion ≈ $1.12 Billion |
CN¥-407.12 Million ≈ $-59.57 Million |
-0.053x | -223.79% |
| 2016-12-31 | CN¥8.09 Billion ≈ $1.18 Billion |
CN¥346.07 Million ≈ $50.64 Million |
0.043x | -57.90% |
| 2015-12-31 | CN¥8.79 Billion ≈ $1.29 Billion |
CN¥893.71 Million ≈ $130.78 Million |
0.102x | -7.00% |
| 2014-12-31 | CN¥8.35 Billion ≈ $1.22 Billion |
CN¥912.80 Million ≈ $133.57 Million |
0.109x | +109.44% |
| 2013-12-31 | CN¥8.07 Billion ≈ $1.18 Billion |
CN¥420.97 Million ≈ $61.60 Million |
0.052x | -11.41% |
| 2012-12-31 | CN¥8.05 Billion ≈ $1.18 Billion |
CN¥473.89 Million ≈ $69.35 Million |
0.059x | -66.83% |
| 2011-12-31 | CN¥7.91 Billion ≈ $1.16 Billion |
CN¥1.41 Billion ≈ $205.63 Million |
0.178x | +301.45% |
| 2010-12-31 | CN¥8.02 Billion ≈ $1.17 Billion |
CN¥354.86 Million ≈ $51.93 Million |
0.044x | -86.70% |
| 2009-12-31 | CN¥1.07 Billion ≈ $156.62 Million |
CN¥355.81 Million ≈ $52.07 Million |
0.332x | +155.03% |
| 2008-12-31 | CN¥307.83 Million ≈ $45.05 Million |
CN¥40.13 Million ≈ $5.87 Million |
0.130x | +37.85% |
| 2007-12-31 | CN¥146.44 Million ≈ $21.43 Million |
CN¥13.85 Million ≈ $2.03 Million |
0.095x | -87.95% |
| 2006-12-31 | CN¥91.33 Million ≈ $13.36 Million |
CN¥71.66 Million ≈ $10.49 Million |
0.785x | -- |
About Shenzhen Hepalink Pharmaceutical Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products,… Read more